Indaptus Therapeutics Files 8-K with Financial Obligations
Ticker: INDP · Form: 8-K · Filed: Jul 1, 2025 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation, equity-sale
TL;DR
Indaptus Therapeutics took on new debt and sold equity on June 30th.
AI Summary
On June 30, 2025, Indaptus Therapeutics, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported unregistered sales of equity securities and provided a Regulation FD disclosure. This filing details significant financial and corporate actions taken by the company.
Why It Matters
This filing indicates Indaptus Therapeutics has entered into new financial obligations and has engaged in equity sales, which could impact its financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details new financial obligations and unregistered equity sales, which can introduce financial risk and dilution.
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Registrant
- June 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40652 (identifier) — SEC File Number
- 86-3158720 (identifier) — IRS Employer Identification No.
- 3 Columbus Circle (address) — Business and Mail Address
FAQ
What type of material definitive agreement did Indaptus Therapeutics enter into?
The filing indicates the entry into a material definitive agreement that resulted in a direct financial obligation for the registrant.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 30, 2025.
What other significant corporate actions are disclosed in this filing?
The filing also discloses the creation of a direct financial obligation, unregistered sales of equity securities, and a Regulation FD disclosure.
What is Indaptus Therapeutics, Inc.'s state of incorporation and SEC file number?
Indaptus Therapeutics, Inc. is incorporated in Delaware and has an SEC file number of 001-40652.
What is the business and mailing address for Indaptus Therapeutics, Inc.?
The business and mailing address for Indaptus Therapeutics, Inc. is 3 Columbus Circle, 15th Floor, New York, NY 10019.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding Indaptus Therapeutics, Inc. (INDP).